Annuity Payment Model For Cures May Get Test Drive In Massachusetts
First-ever implementation of often-discussed reimbursement approach for high-cost drugs would involve group of commercial payers to address “portability” issue and may start with Novartis’ Zolgensma.
You may also be interested in...
Finance Committee chairman wants a provision allowing Medicaid to make installment payments for high-cost curative treatments in drug pricing legislation. But Democrats worry such a model might encourage high prices.
Harvard Pilgrim's Michael Sherman and Cigna's Steve Miller advise gene therapy developers to consider the burden of high cost treatments on Medicaid programs when setting list prices.
MIT Center for Biomedical Innovation is proposing creation of Orphan Reinsurance Benefit Managers as one mechanism to help finance curative cellular and gene therapies. The idea may or may not prove viable – but it is a reminder that “middlemen” aren’t likely going away even if rebates do.